INBP — Integrated Biopharma Income Statement
0.000.00%
Last trade - 00:00
- $6.92m
- $4.92m
- $50.67m
- 65
- 96
- 28
- 66
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 50 | 52.8 | 63.6 | 56.2 | 50.7 |
Cost of Revenue | |||||
Gross Profit | 6.22 | 6.73 | 9.48 | 6.55 | 4.06 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 47.3 | 49.5 | 56.1 | 53.5 | 50.6 |
Operating Profit | 2.7 | 3.26 | 7.44 | 2.75 | 0.12 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2.04 | 3.09 | 7.25 | 2.6 | 0.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1.69 | 4.11 | 8.01 | 3.84 | -0.052 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 1.69 | 4.11 | 8.01 | 3.84 | -0.034 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 1.69 | 4.11 | 8.01 | 3.88 | -0.034 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.057 | 0.132 | 0.216 | 0.12 | -0.002 |